This announcement breaks with the usual workings of the healthcare system, often more comfortable treating illness than preventing it. The French government is investing six million euros over four years, until 2030, to support Interception, a personalized cancer prevention program launched in 2021 by the Gustave Roussy Institute. The objective is clear: to identify high-risk profiles earlier and intervene before the disease takes hold, using a comprehensive care pathway rather than simply offering advice between appointments.
In concrete terms, Interception will expand to two new sites: the Polyclinique du Parc in Valenciennes (Elsan group) in the North and the University Hospital of Réunion, in addition to the five regions already involved: Île-de-France, Auvergne-Rhône-Alpes, Brittany, Nouvelle-Aquitaine, and Provence-Alpes-Côte d'Azur (PACA). The decree formalizing this funding was published in the Official Journal on March 31, with a framework based on Article 51 of the Social Security Financing Law, a provision that authorizes "off-the-beaten-track" experiments when they promise to improve the organization of care.
A bet on "tailor-made" before the diagnosis
The program targets individuals identified as being at increased risk of certain cancers (breast, lung, pancreatic, colon, etc.) due to family history or exposure. Across all sites, 4.350 patients are expected to be reached. In a single day, participants attend consultations (oncology, smoking cessation, etc.) and workshops focusing on nutrition, physical activity, and risk reduction. They then leave with an action plan and personalized follow-up via an app, with the option to quickly contact the center if they have any concerns.
Behind this highly structured format, one can clearly see a political choice: to push forward with the "prevention" focus outlined in the ten-year cancer control strategy for 2021-2030, and to try to reduce territorial inequalities. Reunion Island is not a symbol chosen at random, as disparities in access to screening and certain exposures to risk factors are more pronounced in the French overseas territories. It is also a way of stopping the charade: cancer remains the leading cause of death in France, with more than 433.000 new cases estimated in 2023, and institutions remind us that a significant proportion of patients could have been identified as "at risk" years before their diagnosis.
The very French question remains: how to implement this on the ground? This includes coordination with general practitioners, the role of community medicine, the ability to convince those who feel disconnected from the healthcare system, and ensuring genuine continuity of care beyond the initial day. For Suzette Delaloge, oncologist and director of Interception, "tailor-made prevention, rooted in patients' daily lives and developed in collaboration with community healthcare professionals, is not only possible but also effective." At a time when there is talk of achieving higher screening rates and making HPV vaccination a standard practice, this pilot program will primarily address one question: can prevention finally move from a slogan to a routine?
Community
Comments
Comments are open, but protected against spam. Initial posts and comments containing links undergo manual review.
Be the first to comment on this article.